Table 1.
Author, year | Analysisa | N | Diagnosisb | Type of study | % Female | Mean age | Country |
---|---|---|---|---|---|---|---|
Nielsen14 | II | 136 | BD | C-S | N.K. | N.K. | Denmark |
Malleson et al15 | II, IVc | 14 | MDD | TT | N.K. | N.K. | UK |
Bjørum45 | II, IV | 60 | Depression | TT with C-S | 67 | 51 | Denmark |
Bjørum et al46 | II, IV | 68 | Depression | TT with C-S | 75 | 47 | Denmark |
Naylor et al47 | II, IV | 62 | BD | TT with C-S | 65 | N.K. | UK |
Herzberg & Herzberg48 | II | 119 | MDD | C-S | 41 | 32 | Australia |
Ramsey et al49 | II, IV | 83 | BD, MDD | TT with C-S | 27 | N.K. | USA |
Sengupta et al50 | IV | 131 | BD, MDD | TT with C-S | 48 | N.K. | India |
Strzyzewski et al50 | II, IVc | 46 | BD, MDD | TT | 57 | 37 | Poland |
Frazer et al51 | II, IV | 194 | BD, MDD | C-S | 51 | 46 | USA |
Thakar et al52 | IV | 140 | BD, MDD | C-S | 57 | 40 | Canada |
Alexander et al53 | IV | 47 | BD | C-S | 53 | 34 | Lebanon |
Banki et al54 | II, IV | 34 | MDD | C-S | 100 | 42 | Hungary |
Linder et al55 | II, IV | 83 | (rem) MDD | TT + C-S | 50 | 53 | Sweden |
Kirov et al56 | II, IV | 319 | BD, MDD | TT + C-S | N.K. | 36 | Bulgaria |
Widmer et al57 | II, IV | 53 | BD, MDD | TT + C-S | 49 | 48 | Switzerland |
Widmer et al58 | II, IV | 101 | BD, MDD | C-S | 53 | 46 | Switzerland |
Young et al59 | II | 225 | BD, MDD | C-S | 61 | 37 | Canada |
Kamei et al60 | II, IV | 51 | (rem) MDD | TT + C-S | 35 | 38 | Japan |
Walker et al61 | III | 71 | Depression | TT | 100 | NK | UK |
Levine et al62 | II | 29 | BD, MDD | C-S | 59 | 56 | USA |
De Souza et al | III | 42 | Depression | TT | 100 | 32 | UK |
Zieba et al64 | II | 35 | MDD | C-S | 51 | 40 | Poland |
Imada et al65 | II | 101 | BD, MDD | C-S | 43 | 45 | Japan |
Sharkey et al66 | I | 279 | Depression | C-S | 100 | ~80 | USA |
Hornyak et al67 | III | 11 | Depression | TT | 55 | 47 | Germany |
Bhudia et al31 | III | 273 | Depression | TT | 23 | 64 | USA |
Daini et al68 | II, IV | 162 | MDD | C-S | 24 | 32 | Italy |
Barragan-Rodrìguez et al69 | II | 110 | Depression | C-S | 75 | 77 | Mexico |
Barragan-Rodrìguez et al70 | III | 23 | Depression | TT | 52 | 68 | Mexico |
Iosifescu et al71 | II | 29 | MDD | TT | 57 | 42 | USA |
Nechifor72 | II | 76 | MDD | TT | ~75 | N.K. | Romania |
Jacka et al27 | I | 5708 | Depression | C-S | 57 | 48 | Norway |
Rondanelli et al73 | III | 43 | Depression | TT | 63 | 78 | Italy |
Bae & Kim74 | I, II | 105 | Depression | C-S | 100 | 49 | Rep. of Korea |
Camardese et al75 | II | 123 | MDD | C-S | 54 | 48 | Italy |
Huang et al76 | I, II | 210 | MDD | C-S | 53 | 72 | Taiwan |
Jacka et al77 | I | 1023 | MDD | C-S | 100 | 51 | Australia |
Cubala et al78 | II | 40 | MDD | C-S | 58 | 32 | Poland |
Yary et al79 | I | 402 | Depression | C-S | 43 | 33 | Malaysia |
Büttner et al80 | II | 30 | MDD | TT | 43 | 46 | Germany |
Kim et al81 | I | 849 | Depression | C-S | 100 | 15 | Rep. of Korea |
Miki et al82 | I | 2006 | Depression | C-S | 11 | 42 | Japan |
Misztak et al83 | II | 179 | BD | C-S | 61 | 45 | Poland |
Rajizadeh et al84 | II | 650 | Depression | C-S | 70 | 34 | Iran |
Styczeń et al30 | II | 164 | MDD | C-S | 75 | N.K. | Poland |
Tarleton & Littenberg85 | I | 8894 | Depression | C-S | 53 | 46 | USA |
Fard et al86 | III | 95 | Depression | TT | 100 | 28 | Iran |
Gu et al87 | II | 329 | MDD | PROS + C-S | 37 | 60 | China |
Martínez-Gonzalez et al88 | I | 15 836 | MDD | PROS | 59 | 38 | Spain |
Rubio-López et al89 | I | 710 | Depression | C-S | 52 | 8 | Spain |
Yary et al28 | I | 2320 | Depression | PROS + C-S | 0 | 53 | Finland |
Bambling et al90 | III | 12 | MDD | TT | 66 | 49 | Australia |
Mehdi et al91 | II, III | 12 | MDD | TT | 75 | 47 | USA |
Miyake et al92 | I | 1745 | Depression | C-S | 100 | 31 | Japan |
Rajizadeh et al32 | III | 60 | Depression | TT | 73 | 32 | Iran |
Szkup et al93 | II | 198 | Depression | C-S | 100 | 56 | Poland |
Tarleton et al94 | III | 112 | Depression | TT | 62 | 53 | USA |
ADs, antidepressants; BD, bipolar disorder; C-S, cross-sectional; MDD, major depressive disorder; PROS, prospective; REM, remitted; TT, treatment trial.
This column indicates in which meta-analysis the study in the corresponding row was included:
I Dietary Mg2+ in relation to mood disorder prevalence and incidence; II Mg2+ in bodily fluids of patients and healthy control subjects or Mg2+ in relation to symptom severity; III Mg2+ supplements as an antidepressant; IV additional analyses ([1] differences in Mg2+ levels in bodily fluids between patients with mood v. other psychiatric disorders, [2] pre-post treatment (with antidepressants and/or mood stabilisers) differences in Mg2+ levels in bodily fluids, and [3] Mg2+ ATPase in erythrocytes or platelets; see Results section).
We distinguish depression from MDD here. Depression refers to self-reported symptoms, MDD to the diagnosed syndrome.
This study reported on changes in Mg2+ levels over the course of treatment in a single patient sample only.